Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Clin Cancer Res. 2024 May 1;30(9):1992. doi: 10.1158/1078-0432.CCR-24-0635.NO ABSTRACTPMID:38690594 | DOI:10.1158/1078-0432.CCR-24-0635 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 1, 2024 Category: Cancer & Oncology Authors: Alyssa C Flint Dana K Mitchell Steven P Angus Abbi E Smith Waylan Bessler Li Jiang Henry Mang Xiaohong Li Qingbo Lu Brooke Rodriguez George E Sandusky Andi R Masters Chi Zhang Pengtao Dang Jenna Koenig Gary L Johnson Weihua Shen Jiangang Liu Amit Aggarwal Source Type: research
Editor's Note: Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator
Clin Cancer Res. 2024 May 1;30(9):1996. doi: 10.1158/1078-0432.CCR-24-0857.NO ABSTRACTPMID:38690595 | DOI:10.1158/1078-0432.CCR-24-0857 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 1, 2024 Category: Cancer & Oncology Authors: Gurmeet Kaur Dorina Belotti Angelika M Burger Kirsten Fisher-Nielson Patrizia Borsotti Elena Riccardi Jagada Thillainathan Melinda Hollingshead Edward A Sausville Raffaella Giavazzi Source Type: research
Editor's Note: Activation of NF- κB Is a Novel Target of KRAS-induced Endometrial Carcinogenesis
Clin Cancer Res. 2024 May 1;30(9):1995. doi: 10.1158/1078-0432.CCR-24-1018.NO ABSTRACTPMID:38690596 | DOI:10.1158/1078-0432.CCR-24-1018 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 1, 2024 Category: Cancer & Oncology Authors: Yasunari Mizumoto Satoru Kyo Tohru Kiyono Masahiro Takakura Mitsuhiro Nakamura Yoshiko Maida Noriko Mori Yukiko Bono Hiroaki Sakurai Masaki Inoue Source Type: research
Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Clin Cancer Res. 2024 May 1;30(9):1994. doi: 10.1158/1078-0432.CCR-24-0856.NO ABSTRACTPMID:38690597 | DOI:10.1158/1078-0432.CCR-24-0856 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 1, 2024 Category: Cancer & Oncology Authors: Warren Fiskus Rekha Rao Ramesh Balusu Siddhartha Ganguly Jianguo Tao Eduardo Sotomayor Uma Mudunuru Jacqueline E Smith Stacey L Hembruff Peter Atadja Victor E Marquez Kapil Bhalla Source Type: research
Editor's Note: Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFN β in Glioblastomas
Clin Cancer Res. 2024 May 1;30(9):1993. doi: 10.1158/1078-0432.CCR-24-0858.NO ABSTRACTPMID:38690598 | DOI:10.1158/1078-0432.CCR-24-0858 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 1, 2024 Category: Cancer & Oncology Authors: Sung Hugh Choi Daniel W Stuckey Sara Pignatta Clemens Reinshagen Jasneet Kaur Khalsa Nicolaas Roozendaal Jordi Martinez-Quintanilla Kaoru Tamura Erhan Keles Khalid Shah Source Type: research
Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance
CONCLUSIONS: We identify a previously unappreciated cDC mechanism mediating Treg tumor infiltration after RT. Our findings suggest blocking the cDC1-CCL22-Treg axis augments RT efficacy. αEGFR-IFNα added to RT provided robust antitumor responses better than systemic free interferon administration, and may overcome clinical limitations to interferon therapy. Our findings highlight the complex behavior of cDC after RT and provide novel therapeutic strategies for overcoming RT-driven immunosuppression to improve RT efficacy.PMID:38691100 | DOI:10.1158/1078-0432.CCR-23-3616 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 1, 2024 Category: Cancer & Oncology Authors: Jason Bugno Liangliang Wang Xianbin Yu Xuezhi Cao Jiaai Wang Xiaona Huang Kaiting Yang Andras Piffko Katherine Chen Stephen Y Luo Emile Naccasha Yuzhu Hou Sherry Fu Chuan He Yang-Xin Fu Hua Laura Liang Ralph R Weichselbaum Source Type: research
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
CONCLUSIONS: Toripalimab plus bevacizumab showed a favorable efficacy and safety profile, supporting further studies of this combination regimen as a first-line treatment of advanced HCC.PMID:38687583 | DOI:10.1158/1078-0432.CCR-24-0006 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Yajin Chen Cheng-You Du Shunli Shen Wu Zhang Yunfeng Shan Ang Lyu Jianhui Wu Changzhen Shang Xuan Luo Jinxing Wei Heng Xiao Jianguo Qiu Yunpeng Hua Shutong Wang Ting Wang Shengjie Dai Shuhao Zhang Bingying Xie Yinghao Wu Chunyi Hao Source Type: research
T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma
CONCLUSIONS: Primary resistance is characterized by a low T-cell/MM cell-ratio and Treg-driven immunosuppression, while reduced T-cell fitness due to continuous BsAb-mediated T-cell activation may contribute to development of acquired resistance.PMID:38687588 | DOI:10.1158/1078-0432.CCR-23-3333 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Christie P M Verkleij Chloe A O'Neill Marloes E C Broekmans Kristine A Frerichs Wassilis S C Bruins Carolien Duetz Sandy Kruyswijk Serena R Baglio Sheri Skerget Rocio Montes de Oca Sonja Zweegman Raluca I Verona Tuna Mutis Niels W C J van de Donk Source Type: research
Clinical and genomic landscape of RAS mutations in gynecologic cancers
CONCLUSION: RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA, PTEN, and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.PMID:38687597 | DOI:10.1158/1078-0432.CCR-23-2819 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Ji Son Yingao Zhang Heather Lin Oriol Mirallas Pablo Alvarez Ballesteros Mirella Nardo Natalie Clark R Tyler Hillman Erick Campbell Vijaykumar Holla Amber M Johnson Amadeo B Biter Ying Yuan Lauren P Cobb David M Gershenson Amir A Jazaeri Karen H Lu Pamela Source Type: research
Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification
CONCLUSIONS: Our findings provide insights into understanding the endometrial cancer metabolic landscape and improvement into diagnosis. The metabolic dysregulation described in this paper linked specific metabolites and pathophysiological mechanisms including cellular proliferation, energy supply, and invasion of neighbouring tissues. Furthermore, cervicovaginal metabolite levels related to tumor characteristics, which are used for risk stratification. Overall, development of non-invasive diagnostic can improve both the acceptability and accessibility of diagnosis.PMID:38687603 | DOI:10.1158/1078-0432.CCR-23-2934 (Source:...
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Georgia M Lorentzen Pawel Laniewski Haiyan Cui Nichole D Mahnert Jamal Mourad Matthew P Borst Lyndsay Willmott Dana M Chase Denise J Roe Melissa M Herbst-Kralovetz Source Type: research
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
CONCLUSIONS: Toripalimab plus bevacizumab showed a favorable efficacy and safety profile, supporting further studies of this combination regimen as a first-line treatment of advanced HCC.PMID:38687583 | DOI:10.1158/1078-0432.CCR-24-0006 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Yajin Chen Cheng-You Du Shunli Shen Wu Zhang Yunfeng Shan Ang Lyu Jianhui Wu Changzhen Shang Xuan Luo Jinxing Wei Heng Xiao Jianguo Qiu Yunpeng Hua Shutong Wang Ting Wang Shengjie Dai Shuhao Zhang Bingying Xie Yinghao Wu Chunyi Hao Source Type: research
T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma
CONCLUSIONS: Primary resistance is characterized by a low T-cell/MM cell-ratio and Treg-driven immunosuppression, while reduced T-cell fitness due to continuous BsAb-mediated T-cell activation may contribute to development of acquired resistance.PMID:38687588 | DOI:10.1158/1078-0432.CCR-23-3333 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Christie P M Verkleij Chloe A O'Neill Marloes E C Broekmans Kristine A Frerichs Wassilis S C Bruins Carolien Duetz Sandy Kruyswijk Serena R Baglio Sheri Skerget Rocio Montes de Oca Sonja Zweegman Raluca I Verona Tuna Mutis Niels W C J van de Donk Source Type: research
Clinical and genomic landscape of RAS mutations in gynecologic cancers
CONCLUSION: RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA, PTEN, and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.PMID:38687597 | DOI:10.1158/1078-0432.CCR-23-2819 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Ji Son Yingao Zhang Heather Lin Oriol Mirallas Pablo Alvarez Ballesteros Mirella Nardo Natalie Clark R Tyler Hillman Erick Campbell Vijaykumar Holla Amber M Johnson Amadeo B Biter Ying Yuan Lauren P Cobb David M Gershenson Amir A Jazaeri Karen H Lu Pamela Source Type: research
Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification
CONCLUSIONS: Our findings provide insights into understanding the endometrial cancer metabolic landscape and improvement into diagnosis. The metabolic dysregulation described in this paper linked specific metabolites and pathophysiological mechanisms including cellular proliferation, energy supply, and invasion of neighbouring tissues. Furthermore, cervicovaginal metabolite levels related to tumor characteristics, which are used for risk stratification. Overall, development of non-invasive diagnostic can improve both the acceptability and accessibility of diagnosis.PMID:38687603 | DOI:10.1158/1078-0432.CCR-23-2934 (Source:...
Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Georgia M Lorentzen Pawel Laniewski Haiyan Cui Nichole D Mahnert Jamal Mourad Matthew P Borst Lyndsay Willmott Dana M Chase Denise J Roe Melissa M Herbst-Kralovetz Source Type: research
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer
CONCLUSIONS: Adding ipilimumab to AAPA did not improve outcomes in men with androgen responsive mCRPC. Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.PMID:38683200 | DOI:10.1158/1078-0432.CCR-23-3740 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 29, 2024 Category: Cancer & Oncology Authors: Ana M Aparicio Rebecca S S Tidwell Shalini S Yadav Jiun-Sheng Chen Miao Zhang Jingjing Liu Shuai Guo Patrick G Pilie Yao Yu Xingzhi Song Haswanth Vundavilli Sonali Jindal Keyi Zhu Paul V Viscuse Justin M Lebenthal Andrew W Hahn Rama Soundararajan Paul G C Source Type: research
